Assessment of 1183 screen-detected, category 3B, circumscribed masses by cytology and core biopsy with long-term follow up data by Farshid, G et al.
Assessment of 1183 screen-detected, category 3B, circumscribed
masses by cytology and core biopsy with long-term follow up data
G Farshid*,1, P Downey
1, PG Gill
1 and S Pieterse
1
1BreastScreen SA, 1 Goodwood Road, Wayville 5065, South Australia
Discrete masses are commonly detected during mammographic screening and most such lesions are benign. For lesions without
pathognomonically benign imaging features that are still regarded likely to be non-malignant (Tabar grade 3) reliable biopsy results
would be a clinically useful alternative to mammographic surveillance. Appropriate institutional guidelines for ethical research were
followed. Between Jan 1996–Dec 2005 grade 3B discrete masses detected in the setting of a large, population based, breast cancer
screening programme are included. Patient demographics, fine needle aspiration biopsy (FNAB), core and surgical biopsy results are
tabulated. The final pathology of excised lesions was obtained. Information regarding interval cancers was obtained from the State
Cancer Registry records and also through long term follow-up of clients in subsequent rounds of screening. A total of 1183 lesions,
mean diameter of 13.3mm (±8.3mm) and mean client age of 55.1 years (±8.8 years) are included. After diagnostic work up, 98
lesions (8.3%) were malignant, 1083 were non-malignant and a final histologic diagnosis was not established in two lesions. In the 27
months after assessment, no interval cancers were attributable to these lesions and during a mean follow up of 54.5 months, available
in 84.9% of eligible women, only one cancer has developed in the same quadrant as the original lesion, although the two processes
are believed to be unrelated. FNAB performed in 1149 cases was definitive in 80.5% cases (882 benign, 43 malignant) with a negative
predictive value (NPV) of 99.8% (880 of 882) and a positive predictive value (PPV) of 95.2% (40 of 42, both intraductal papillomas).
Core biopsy was performed in 178 lesions, mostly for indefinite cytology. Core biopsy was definitive in 79.8% cases (57% benign 22%
malignant) with a PPV of 100% and NPV of 99.0%. In experienced hands FNAB is an accurate first line diagnostic modality for the
assessment of 3B screen-detected discrete masses, providing definitive results in 80.5% of cases. When used as a second line
modality, core biopsy had a similarly high rate of definitive diagnosis at 79.8%. The stepwise approach to the use of FNAB and core
biopsy would reduce substantially the proportion of cases requiring surgical diagnostic biopsy. Given the low probability of malignancy
and the imperative to limit the morbidity associated with cancer screening, the demonstration of the reliability of FNAB as a minimally
invasive but highly accurate test for this particular subset of screen-detected lesions has significant clinical utility.
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Discrete, circumscribed masses constitute one of the most
common groups of lesions encountered during mammographic
screening for breast cancer. Such lesions are encountered in
approximately 8% of all screening mammograms (Stomper et al,
1991) and most are benign (Pisano, 1997).
In the setting of mammographic screening for breast cancer,
lesions with characteristically benign mammographic features do
not require further assessment. When the mammographic features
are not entirely typical of benign lesions, recall for further imaging
assessment is indicated (Sickles, 1997). The use of specific imaging
techniques, such as magnification views, spot compression and
sonography enable radiologists to diagnose cystic lesions and
visualise lesions’ contours better, thus determining the benign
nature of a high proportion of such lesions with confidence
(Kerlikowske et al, 2005). However, some cases remain indetermi-
nate despite the additional imaging. Several options are available
as the next steps in the management of such lesions. These include
surgical excision, core biopsy, fine needle aspiration biopsy or
mammographic surveillance.
In the setting of population based screening for breast cancer,
where most screen-detected lesions are likely to be benign, the aim
to minimise the morbidity associated with cancer screening
requires that the use of surgical biopsy be strictly limited to those
few cases where imaging and needle biopsy techniques cannot
determine the nature of the lesion. Apart from the desire to
minimise surgery for benign disease, the large case volume
discourages widespread use of open biopsy, and to a lesser extent
core biopsy, for pragmatic and economic reasons. The strategy of
short-term mammographic follow up is supported by long-term
follow up data (Sickles, 1991, 1994; Varas et al, 1992). However,
since delay in the diagnosis of breast cancer is a source of anxiety
for women and their doctors, some clinicians may be uncomfor-
table with this approach. In this regard, Sickles notes that while
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spatients are initially enthusiastic about the option of short-term
mammographic follow up, compliance with the full surveillance
protocol was only 45% (Sickles, 1991, 1997).
Fine needle aspiration biopsy (FNAB) is a cost-effective method
of investigating breast lesions. In experienced hands and for
appropriately selected lesions this test is clinically useful and
reliable (Farshid and Downey, 2005). In our programme we use
FNAB as a first line diagnostic modality for the assessment of
category 3 mass lesions, supplemented where necessary, by core
biopsy and surgical biopsy. In the light of the increasing use of
core biopsy in preference to FNAB by other programmes, we
wished to establish the reliability of benign cytology for this
specific category of screen-detected masses through review of
long-term outcome data.
MATERIALS AND METHODS
The design of our breast cancer-screening programme
BreastScreen South Australia is part of a national breast
cancer screening programme and has been accredited to provide
this service since 1991. The design of this programme has
been described previously (Farshid and Rush, 2004). In brief,
asymptomatic women aged 50–69 years are invited to participate
at 1or 2 yearly intervals, depending on family history.
Two radiologists read two view screening mammograms indepen-
dently. A third reader arbitrates discordant results. Using the
Tabar 5-tier grading scheme (Tabar and Dean, 1983), lesions
are assigned to one of five radiologic grades: grade 1, normal;
grade 2, benign; grade 3, indeterminate/equivocal, grade 4,
suspicious for malignancy and grade 5, radiologically malignant.
Clients with grade 1 or 2 lesions are ‘cleared’ and are invited
to return for re-screening in 1–2 years. Lesions graded 3 and
above are recalled for further assessment. Based on work up
mammography and, in most cases, ultrasound examination, the
lesion is re-graded and biopsy is performed on those lesions that
have not been cleared. Fine needle aspiration (FNAB) has been the
initial method of biopsy. More recently, core biopsy has
been adopted as the initial method of evaluation of most
microcalcifications.
The cytologic smears are reported immediately and are
classified into one of five diagnostic categories, based on published
guidelines (NHSBSP, 2001). The cytologic categories are: unsatis-
factory, benign, atypical/indeterminate, suspicious and positive.
Protocols are in place for the further management of each
combination of imaging and cytologic findings. Lesions with
concordant benign findings (grade 3 with benign cytology) are
cleared and are invited for re-screening in 2 years. We liaise with
the primary care providers and the State Cancer Registry and are
required to be notified of any interval cancers diagnosed in our
clients. Lesions with concordant malignant findings (grade 5 with
positive cytology) are referred for treatment. Until July 2003 this
was also the case for grade 4 lesions with positive cytology. Since
then we have required core biopsy confirmation of these
diagnoses. Core biopsy may also be performed on grade 5 lesions
to clarify the nature of the carcinoma. Lesions with discordant or
indefinite FNAB results are assessed by core biopsy. All positive
cytology is re-read the next day by an independent second
pathologist. We obtain the final histology for all surgical
specimens of our clients. All data are continuously audited and
prospectively entered into an electronic database.
Our National Accreditation Standards (BreastScreenAustralia,
2005) require that we be notified by the State Cancer Registry of
any cancers diagnosed in our clients within 27 months of a
negative screen. In addition, breast surgeons and general
practitioners also notify us of any breast cancer diagnoses in our
clients.
Study design
The procedures followed in this study were in accordance with our
institutional ethical standards and the research was approved by
the appropriate institutional review committees.
Discrete solid masses without definite malignant features but
with some deviation from the benign criteria are categorised as
grade 3B and form the study cases. This is a modification of the
Nottingham grading scheme for equivocal lesions, with the ‘B’
referring to the requirement for demonstration of benign epithelial
cells on cytology before recommending routine recall. We searched
our electronic archives for lesions screened during the period
January 1996 to December 2005 in which the dominant radiologic
abnormality was coded as a discrete mass, graded radiologically as
3B. For each lesion we tabulated patient demographics, lesion size,
biopsy methods and outcome. For lesions that were not excised we
obtained follow up information by tracking the clients in our own
database during their subsequent screening visits and through the
State Cancer Registry.
Radiologic characteristics
Lesions we regard as likely to be benign have the following
characteristics on screening mammograms: sharp margins, low
density (but higher than the density of fat), smoothly rounded
contours and usually solitary. Lesions with characteristically
benign mammographic features, such as typical intramammary
nodes, hamartomas, lipomas, oil cysts and typical fibroadenomas
are usually not recalled for further assessment. When the imaging
features are not typical of a benign lesion but still suggest a
probably benign mass, the lesion is graded as 3B and recall for
additional imaging is required.
For solid circumscribed masses magnification views, and if
necessary, spot compression views are performed. These addi-
tional imaging studies assist in excluding malignancy in many
cases.
Sonography is particularly useful in distinguishing between
solid masses and simple cysts but also has high discriminative
value in separating benign solid masses from invasive carcinoma
(Stavros et al, 1995; Skaane and Engedal, 1998; Chao et al, 1999;
Chen et al, 2004).
RESULTS
Case selection
For the time period between January 1996 to December 2005 there
are 1183 lesions in our database in which the dominant screen
detected abnormality is classified as a category 3B discrete mass.
Demographic data
The number of such cases assessed each year ranged from 61 to
169 lesions per year, with a mean of 118.3 lesions per year. In line
with the general expansion of our programme, there has been a
steady increase in the number of these lesions assessed over time.
In relative terms, they constitute 24.4% of all lesions biopsied. The
mean age of the clients was 55.1 years (std 8.8 years, range 40–86
years). Eighty women (6.8%) gave a very strong family history of
breast cancer, 1103 women did not (93.2%). In 387 lesions (32.7%)
the client had been using hormone replacement therapy (HRT).
794 women had not used HRT (67.1%). This information is
unavailable in two cases.
Five hundred and thirty eight lesions (45.5%) were detected in
the first round of screening and the remainder in subsequent
rounds (rounds 2–12). The lesion was located in the right breast in
48.1% of cases and in the left breast in 51.9%.
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sImaging features
In 1001 lesions (84.6% of cases) there was only one lesion. In the
remaining 182 lesions (15.4%) a second lesion was also present
requiring assessment. By definition, this other lesion was
radiologically of grade 3 or higher. The imaging features of a
typical discrete mass included in this study are depicted in
Figure 1. This was shown to be a fibroadenoma. The location of the
mass was specified in all but five cases. The upper outer quadrant
was the most common site (43.5%), followed by the central region
(17.5%), upper inner quadrant (15.4%), lower inner quadrant
(11.7%), axillary tail (0.8%) and nipple (0.7%). The mean diameter
was 13.3mm (std 8.3mm, range 2–120mm).
Final outcome
After diagnostic work up, tissue biopsy and long term follow up via
two independent means, ninety-eight cases (8.3%) were proven to
be malignant. These comprised 66 invasive, 26 in situ carcinomas
and six other neoplasms. This latter group included one primary
leiomyosarcoma, three cases of lymphoma, one case of metastatic
renal cell carcinoma and one intramammary node with metastatic
breast cancer. Of the remaining lesions 1083 have been established
to be non-malignant (91.5%). A final diagnosis was not specified in
the database for two lesions.
Cytology
Fine needle aspiration biopsy was performed in 1149 cases
(97.1%). Cytology was interpreted as benign in 882 cases
(76.8%), atypical in 125 (10.9%), suspicious in 44 (3.9%),
malignant in 43 lesions (3.7%) and inadequate in 55 (4.8%). FNAB
was not performed in 32 cases, mostly because core biopsy was
used as the initial method of assessment at the discretion of the
assessment team. The morphology of three different lesions in this
study, each assessed by FNAB and core biopsy, are depicted in
Figures 2–4.
The correlation of the cytologic results against the final
diagnosis is given in Table 1. Eight hundred and eighty of 882
(99.8%) lesions with benign cytology were benign. The two false-
negative cases were both ductal carcinoma in situ (DCIS). In one
case the cytology was interpreted as benign but some papillary
features were noted. Since we recommend excision of papillary
lesions, open biopsy was performed. This lesion was found to be a
papillary and cribriform DCIS, eventually requiring mastectomy
for complete excision. The second case had benign cytology. On
excision for treatment of an adjoining higher grade lesion, the
category 3 mass was found to comprise an area of fibrocystic
change with a small focus of high grade DCIS. It is likely that the
malignant focus in this mass was not sampled by FNAB.
In all 40 of 42 lesions (95.2%) with malignant cytology were
malignant, amounting to a false-positive rate of 4.8%. The cases
with false-positive cytology were both intraductal papillomata. The
likelihood of malignancy was 18.4% among lesions with atypical
cytology and 63.6% for lesions with suspicious cytology. Among
lesions that were ultimately proven to be benign, but had initially
produced suspicious cytology, fibroadenoma was the commonest
lesion (six cases), followed by reactive lymph nodes (three lesions),
and one case of each of papilloma, hamartoma, usual ductal
hyperplasia and atypical ductal hyperplasia.
Pattern of use of core biopsy
Core biopsy was used in 178 lesions in this series (15%). In 158
cases this followed FNAB. Core biopsy was required due to
indefinite cytology in 126 cases comprising 35 cases with
inadequate cytology, 69 with atypical cytology, and 22 with
suspicious cytology. In 32 other cases core biopsy was performed
to confirm positive cytology results (19 cases), or benign cytology
results (13 cases) at the discretion of the assessment team. Core
biopsy was the primary biopsy modality in remaining 20 cases.
Table 2 shows the correlation between the core biopsy results
and the final diagnosis. Core biopsy provided a definitive benign
A
B
C
Figure 1 Typical imaging features of a probably benign, circumscribed, discrete mass, graded 3B in our programme. (A) Mammogram, left lateral view,
with the arrow pointing to a circumscribed mass. (B) Breast ultrasound of the lesion, showing a circumscribed oblong mass. (C) Ultrasound image,
documenting the presence of the biopsy needle within the lesion.
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sor malignant diagnosis in 79.8% of cases. One of 102 cases with
benign core biopsy had positive cytology and was ultimately found
to be malignant at surgery, the core being non-representative. The
negative predictive value (NPV) of a benign core biopsy diagnosis
was 99.0%. The positive predictive value (PPV) of a malignant core
biopsy was 100%. The few cases with suspicious core biopsy
findings were found to be malignant in 71.4% of cases and those
with atypia on core biopsy were malignant in 7.1% of cases.
In 158 cases core biopsy followed cytologic assessment. Table 3
shows these results. When core biopsy followed insufficient,
atypical or suspicious FNAB, it established a definitive benign or
malignant diagnosis in 77.8% of cases (98 of 126 cases). Core
A B
C D
Figure 2 Biopsy features of a case shown to be a fibroadenoma. (A) Low power photomicrograph of a fine needle aspiration biopsy of a discrete solid
mass, showing mono-layered sheets of cohesive cells in a background of bipolar cells. (B) Cohesive sheet of cells together with smaller cell clusters with a
tendency to dissociation. (C) Higher power view showing small, loosely aggregated cells with mild nuclear enlargement and variability. In view of these
features, core biopsy was performed. (D) Core biopsy demonstrating features of a fibroadenoma with mild hyperplasia in some ducts.
A
C
B
D
Figure 3 Biopsy features of a fibroadenoma accompanied by a focus of high grade DCIS. (A) Low power view of a smear showing cohesive clusters of
orderly cells (arrow), together with a dispersed population of large, atypical cells (left side of picture). (B) Higher power view of a small cluster of atypical
cells, showing nuclear enlargement, variability and irregularity of nuclear membranes. (C) Core biopsy showing a fibroadenoma accompanied by one focus of
high-grade DCIS (arrow). (D) Higher power view of the area of DCIS arising in a fibroadenoma. High-grade nuclear features and comedo necrosis are
evident.
Biopsy assessment of screen-detected ‘category 3B’ discrete masses
G Farshid et al
1185
British Journal of Cancer (2008) 98(7), 1182–1190 & 2008 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sbiopsy was positive for malignancy in 2.9% cases with inadequate
cytology, 11.6% cases with atypical cytology, 50% of those
following suspicious cytology and in 89.5% after positive cytology.
In 19 cases with positive cytology, core biopsy was reported as
malignant in 17 of these cases, suspicious in one case and benign
in one case. Ultimately, all 19 lesions were indeed malignant, 17
invasive and two in situ carcinomas. Core biopsy was therefore
helpful in distinguishing the two cases of DCIS from invasive
cancers. The one case with benign core biopsy was a false negative
due to a sampling problem. In no case with a prior benign
cytologic diagnosis did core biopsy show malignancy.
Overall, the core biopsy results were definitive in 79.8% of the
cases: this included definite benign results in 57.3% of cases and a
definite malignant diagnosis in 22.5%. The remaining 20.2% of
cases had indefinite core biopsy results, including those with
atypical, suspicious or nonrepresentative cores, all of which
required further investigation.
Cases with final histologic diagnoses
Cases assessed with cytology are categorised according to the
5-tiered diagnostic system described above, but a specific tissue
diagnosis is usually not possible in the majority of cases. A specific
histologic diagnosis is available in the database in 271 lesions,
principally from surgical specimens.
As shown in Table 4 malignancy was documented in 98
of the discrete screen-detected masses in this series. Ductal
carcinoma of no special type was the most common carcinoma,
followed by mucinous carcinoma. Two tubular carcinomas and
one case each of medullary and lobular carcinoma also presented
in this manner. Among the malignant lesions there were three
cases of lymphoma, one primary breast leimyosarcoma, one
metastatic deposit of renal cell carcinoma to the breast parench-
yma and one case of an intramammary node bearing metastatic
breast cancer.
Among the 66 invasive cancers, infiltrating ductal carcinoma of
no special type constituted 74.2% of the lesions, while special type
cancers together accounted for 25.8%. Grade I tumours were the
most frequent cancer, accounting for 49.2% of the cases. Only
17.5% of the cancers were grade 3, and the remaining 33.3% were
grade 2. Grade was not specified for three cases.
Of the 25 DCIS cases that presented as a discrete solid mass, only
four were of high grade. Many of the DCIS cases in this series had a
papillary component.
As we do not advise surgery for the vast majority of lesions
found to be benign on biopsy, a specific histologic diagnosis is
available in only a small proportion of these cases. As shown in
Table 4, fibroadenoma was the most common benign diagnosis,
followed by intraductal papilloma, fibrocystic changes, including
ductal hyperplasia and inspissated cysts.
Phyllodes tumour was diagnosed through pathological assess-
ment of the excised mass in seven lesions. Six of these were of the
benign subtype and one case was a borderline lesion. There were
no instances of malignant phyllodes tumour among this series of
screen detected discrete category 3 mass lesions.
A
B
C
Figure 4 Biopsy features of an intraductal papilloma. (A) Low power photomicrograph showing a highly cellular smear, composed of variable sized,
cohesive clusters of orderly cells, numerous bare bipolar cells and some dissociated cells. (B) Higher power view of a cellular cluster showing branching
fibrovascular cores, suggestive of a papillary lesion. (C) Core biopsy confirming an intraductal papilloma.
Table 1 Correlation of cytologic results against final diagnoses for the
1147 lesions assessed by fine needle aspiration biopsy
Final diagnostic category
Malignant Non-malignant Total
FNA biopsy results
Benign 2 (0.2%) 880 (99.8%) 882 (76.9%)
Atypical 23 (18.4%) 102 (81.6%) 125 (10.9%)
Suspicious 28 (63.6%) 16 (36.4%) 44 (3.8%)
Positive 40 (95.2%) 2 (4.8%) 42 (3.7%)
Insufficient for diagnosis 1 (1.9%) 53 (98.2%) 54 (4.7%)
1147
FNAB¼fine needle aspiration biopsy
Table 2 Correlation between core biopsy results and final diagnoses for
the 178 lesions assessed by core biopsy
Final diagnostic category
Malignant Non-malignant Total
Core biopsy results
Benign 1 (1.0%) 101 (99.0%) 102 (57.3%)
Atypical 2 (7.1%) 26 (92.9%) 28 (15.7%)
Suspicious 5 (71.4%) 2 (28.6%) 7 (3.9%)
Positive 40 (100%) 0 40 (22.5%)
Insufficient or non-diagnostic 1 (100%) 0 1 (0.6%)
178
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sFurther follow-up
The records of the State Cancer Registry show that there was one
interval cancer diagnosed within 27 months of the screening round
of interest and that cancer affected the contralateral breast.
Tracking the clients with non-malignant findings during their
subsequent rounds of screening showed that 781 of the 920
(84.9%) eligible women returned for subsequent rounds of
screening. The mean period of follow-up was 54 months, (range
10.5–130.3 months). During this time seven women developed
breast cancer, five invasive and two DCIS. As can be seen in
Table 5, in seven of eight cases these cancers either affected the
opposite breast or a different quadrant than the index lesion. The
final case was a benign complex cyst on FNAB. Six years later
microcalcifications were detected in the same quadrant during
screening mammography. These were shown to be associated with
DCIS of intermediate grade.
DISCUSSION
The aim of population-based screening for breast cancer is the
reduction in mortality from breast cancer through early detection,
achieved with minimal morbidity (BreastScreenAustralia, 2005).
Because of its contribution to the morbidity and anxiety associated
with cancer screening, the benign biopsy rate is one of the key
performance indices for screening programmes. BreastScreen
Australia’s National Accreditation Standards mandate that the
use of open biopsies for non-malignant lesions not exceed 0.35%
for women having their first screen and 0.16% for subsequent
rounds of screening. Discrete rounded masses are among the most
common group of abnormalities detected during screening
mammography. Stomper et al (1991) found well-circumscribed
nodules in 13.3% of 1500 screening mammograms. Even when
lesions with features of benign intramammary nodes were
excluded, such lesions were found in 6.0% of screening
mammograms. Many lesions with pathognomonically benign
imaging features on screening mammograms are not assessed
further, and a high proportion of the remaining lesions can be
established to be benign through the use of mammographic work
up and sonography (Stavros et al, 1995; Skaane and Engedal, 1998;
Chao et al, 1999; Chen et al, 2004). Lesions that remain
indeterminate despite the additional imaging still represent a
sizable group, particularly if they were to be assessed by surgical
biopsy. In our programme such lesions comprise 24.4% of all
screen-detected lesions requiring tissue diagnosis. Since these
lesions are likely to be benign, careful case selection for open
biopsy is required to minimise the benign biopsy rate.
A variety of approaches are utilised for establishing the nature of
these indeterminate, but still probably benign lesions. Depending
on local expertise and conventions, short interval mammographic
surveillance, fine needle aspiration biopsy, core biopsy and open
biopsy have been advocated.
The attraction of mammographic surveillance is that the
morbidity and costs associated with screening are minimised,
particularly when the only available alternative is open biopsy.
Sickles has reported the results of a prospective study of 1403 such
women with periodic follow up for at least 36 months. During this
time 1.4% of the cohort recommended for mammographic
surveillance were diagnosed with invasive carcinoma, almost all
detected as a result of interval mammographic change or by
becoming palpable (Sickles, 1994). A significantly higher like-
lihood of malignancy was not found among circumscribed masses
in that study where the lesion diameter was in the 10–15mm range
or where the woman was older than 50 years, as cancer was
diagnosed in 1.6 and 1.7% of the cases respectively. Such data
Table 4 Final histology of selected lesions forming discrete masses on
screening mammograms
Final diagnosis of selected lesions forming a discrete screen-detected
mass
Diagnosis Number of lesions %
Invasive ductal carcinoma, NOS 49 18.08
Mucinous carcinoma 13 4.80
Tubular carcinoma 2 0.74
Medullary carcinoma 1 0.37
Lobular carcinoma 1 0.00
DCIS, including papillary 25 9.23
LCIS 1 0.37
Leiomyosarcoma 1 0.37
Lymphoma 3 1.11
Metastasis 1 0.37
Nodal metastasis 1 0.37
ADH 7 2.58
ALH 1 0.37
Cyst 20 7.38
Fibroadenoma 57 21.03
Intraductal papilloma 30 11.07
Fibrocystic changes 28 10.33
Sclerosing Adenosis 4 1.48
Hamartoma 4 1.48
Lymph node, reactive 10 3.69
Mucocele 1 0.37
Myxoma 1 0.37
Myofibroblastoma 1 0.37
Phyllodes, benign 6 2.21
Phyllodes, borderline 1 0.37
Hemangioma 1 0.37
Tubular adenoma 1 0.37
Total 271
ADH¼atypical ductal hyperplasia; ALH¼atypical lobular hyperplasia; DCIS¼ductal
carcinoma in situ;L C I S¼lobular carcinoma in situ; NOS¼not otherwise specified.
Table 3 Core biopsy after FNA biopsy
Core biopsy results
Insufficient Benign Atypical Suspicious Positive Total
FNA biopsy results
Insufficient 0 32 (91.4%) 2 (5.7%) 0 1 (2.9%) 35 (22.2%)
Benign 0 9 (69.2%) 4 (30.8%) 0 0 13 (8.2%)
Atypical 0 41 (59.4%) 18 (26.1%) 2 (2.9%) 8 (11.6%) 69 (43.7%)
Suspicious 1 (4.6%) 5 (22.7%) 1 (4.6%) 4 (18.2%) 11 (50%) 22 (13.9%)
Positive 0 1 (5.3%) 0 1 (5.3%) 17 (89.5%) 19 (12.0%)
158
FNAB¼fine needle aspiration biopsy
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sprovide some justification for mammographic surveillance as a
plausible method of dealing with mammographically benign mass
lesions. However, in Sickles’s study only 68.3% complied with the
follow-up regimen to 36–43 months. This significant attrition rate,
when coupled with the fact that delay in the diagnosis of
malignancy is one of the chief factors in medico-legal disputes
concerning breast disease causes many clinicians to be uncomfor-
table with the watchful waiting approach.
Cytology as a first line diagnostic modality for discrete
rounded screen-detected lesions
In our programme a tiered approach to biopsy is applied, using a
combination of FNAB and core biopsy with referral of highly
selected cases for surgical excision. Breast cytology requires a high
level of expertise but our data demonstrate that in experienced
hands FNAB is a reliable first line diagnostic modality for
assessment of discrete, probably benign masses. Benign
cytology had a negative predictive value of 99.8% and positive
cytology results had a positive predictive value of 95.2%. The NPV
of benign cytology compares favourably with the 99.0% NPV of
core biopsy, although cases were selected for core biopsy because
they had already proven challenging on cytology.
Since a definite benign cytologic diagnosis has a rather high
NPV for category 3 masses, we do not advocate further diagnostic
tests for this group of clients. They are recommended to return for
their next round of screening, usually in 2 years. This approach
thus obviates the need for further, more invasive investigations in
76.8% of clients. The PPV of cytology for this group of lesions is
also high, but at 95.2%, it is not sufficiently reliable for definitive
surgical management (Farshid and Downey, 2005). Our current
protocols therefore require confirmation of malignancy by core
biopsy in category 3 masses with positive cytology.
It is noteworthy that only 4.7% of the 1147 lesions assessed by
FNAB produced an inadequate sample. This is even lower than the
8.7% rate of inadequacy for the entire group of lesions (Farshid
and Downey, 2005). The high rates of inadequate samples of FNAB,
ranging up to 58.7% in some reports has contributed to
discouraging the use of this technique (Ibrahim et al, 2001).
We believe that the presence of on-site pathologists is key in this
achievement, as samples can be examined immediately and
re-aspiration may be undertaken if necessary. It is also a reflection
of having a team of radiologists experienced in sampling the
lesions.
The value of core biopsy
As well as requiring confirmation of malignancy in discrete mass
lesions with positive cytology, lesions with indefinite cytology,
inclusive of those with atypical, suspicious and non-diagnostic
results, require core biopsy assessment to establish their nature. In
this series, these cases together comprise only 23.1% of all
probably benign mass lesions. Thus, theoretically the use of
cytology limits the morbidity and costs associated with core biopsy
to this subset of clients. In this series, 15% of the lesions were
assessed by core biopsy, mostly due to inadequate, indefinite or
discordant cytology results. The difference between this figure and
the 23.1% prediction is due to the fact that our protocols have
evolved over the time period under study to limit the use of open
biopsy. Furthermore, some flexibility in the use of open biopsy is
permitted, to accommodate specific clinical situations.
When used for the above indications, core biopsy was a useful
second line diagnostic modality, resulting in a definitive diagnosis
in 79.8% of the cases and leaving only 3.0% of the total cases
requiring further assessment, mostly by open biopsy. Unlike
cytology, there were no false positive diagnoses with core biopsy,
resulting in a PPV of 100%. Core biopsy was also useful in
discriminating between in situ and invasive cancers. We note that
the NPV of benign core biopsy was 99.0%, whereas that of benign
FNAB was 99.8%. Far fewer cases were subjected to core biopsy,
such that the one false-negative case from sampling error had a
large effect on the NPV. Nevertheless, this case points out another
advantage of using more than one biopsy technique. The cytology
in this case was already positive, casting doubt on the representa-
tiveness of a benign core biopsy sample. We therefore view the two
techniques as complementary.
With the stepwise approach to the use of the available diagnostic
techniques, cytology reduces the proportion of cases requiring
core biopsy to 23.1%, and the open biopsy rate falls to 3% when
following core biopsy. These figures represent significant reduc-
tions in morbidity and cost, particularly since the diagnostic
accuracy of the assessment process has not been compromised.
Long-term follow up
One of the most important aspects of this study is the long-term
follow up data presented. Alignment of our client database with the
State Cancer Registry records reassures us that none of the clients
discharged for routine recall, developed an interval cancer
attributable to the lesion in question in the 27 months after
Table 5 Cancers diagnosed in subsequent rounds of screening in women with benign discrete mass lesions
Subsequent cancers
Case
Location of
cancer Interval Comment
A Same quadrant 6 years 3B mass was a cyst that collapsed after aspiration. Cytology benign. 6 years later developed
microcalcifications detected by screening and intermediate grade DCIS was diagnosed.
B Different quadrant 3 years 3B mass in R UIQ was a fibroadenoma by cytology. Subsequent stellate lesion in R UOQ was an
invasive grade 3 ductal carcinoma.
C Different quadrant 5 years 3B lesion was a fibroadenoma, excised from L LIQ. Subsequent stellate mass in L UOQ was a 9mm
invasive grade 1 ductal carcinoma.
D Other breast 2 years 3B lesion was a reactive node by cytology. 26 months later developed a 16mm grade 2 invasive ductal
carcinoma in the opposite breast. Node negative.
E Other breast 3 years 3B mass was a cyst. Subsequent tumour was a 20mm grade 3 invasive cancer with one positive node.
F Other breast 4 years 3B lesion was a fibroadenoma by cytology. Invasive high-grade cancer developed in the other breast
within 23 months of her latest screen.
G Other breast 4 years 3B mass was a cyst. 4 years later, a 9mm invasive ductal carcinoma was diagnosed within 24 months of
latest screen.
H Other breast 6 years 3B lesion was a fibroadenoma on cytology. Microcalcifications in the other breast led to the diagnosis of
invasive cancer and DCIS.
DCIS¼ductal carcinoma in situ
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sassessment of their discrete mass lesion. Furthermore, at least
84.9% of eligible clients have returned for subsequent rounds of
screening and with a mean follow up of 54.5 months (R 10.5–130.3
months) we have established that none of the lesions recom-
mended for routine re-screening were malignant. This additional
follow-up is crucial in bolstering confidence in the results of our
combined clinical, radiologic and cytologic assessment of these
lesions.
The rarity of phyllodes tumour
Fibroadenoma is one of the most common lesions presenting as a
discrete mass on screening mammograms. One of the sources of
concern in the non-surgical management of fibroepithelial lesions
is the overlap in the imaging and cytology, and to a lesser extent
core biopsy, features of fibroadenoma and phyllodes tumour. This
may lead to surgery even when biopsy suggests fibroadenoma. Our
data demonstrate that in the setting of a population based breast
cancer-screening programme, most such surgery would be for
fibroadenomas. Only seven phyllodes tumors were diagnosed,
constituting 0.6% of the total group, and while one case was
designated borderline, none of the lesions were malignant. It
would appear that malignant phyllodes tumour either occurs rarely
in the screening target age group but when it does occur, its
imaging features are other than a discrete rounded mass.
Nature of lesions
Malignant lesions were diagnosed in 8.3% of the cases presenting
as discrete screen-detected masses. Invasive ductal carcinoma of
no special type constituted the largest subtype, but special type
cancers, including mucinous and medullary carcinomas, together
comprised 25.8% of the invasive cancers. In line with most screen-
detected cancers, the tumours were overwhelmingly of grade I, and
17.5% were classified as grade III.
Of interest was the presentation of DCIS as a discrete rounded
mass in 25 cases. This is an unusual but well documented
presentation for DCIS (Farshid et al, 2007). Only four were of high
grade, while many had a papillary component. This is in contrast
with the typical presentation of screen detected DCIS, which is as
microcalcifications and histologically is associated with comedo-
necrosis and high nuclear grade.
A metastatic deposit of renal cell carcinoma, metastatic breast
cancer to a lymph node, a primary breast leiomyosarcoma and
lymphoma were among the non-epithelial malignancies that
produced discrete circumscribed masses.
Safeguards
Certain non-malignant lesions produce atypical features on
cytology and are a potential source of false-positive cytologic
diagnoses. Papillary lesions, fibroadenomas, ductal proliferative
processes, intra-mammary nodes and hamartomas were among
such lesions in this series. Papillary lesions are a particular
challenge since they may produce smears of abundant cellularity
with dissociation and significant cytologic atypia. The demonstra-
tion of branching fibrovascular cores, anatomical borders in some
cell groups and palisades of cells provide important clues to the
papillary nature of the lesion (Orell and Miliauskas, 2005).
A feature that we find particularly useful in limiting false-positive
diagnoses is the requirement for the absence of benign epithelial
groups before a definite malignant cytologic diagnosis is made
(Orell, 1999). If benign groups are present, the category of
suspicious for malignancy is used, regardless of the degree of
atypia in the remainder of the smear. Another safeguard is the
independent review of all positive cytologic diagnoses by a second
cytopathologist the following day. Finally, in recent years we have
required core biopsy confirmation of all grade 3 discrete mass
lesions with positive cytology.
CONCLUSIONS
Discrete mass lesions detected during population-based screening
mammography are common and most such lesions are non-
malignant. Even among the subset of such lesions recommended
for biopsy only 8.3% were malignant. In experienced hands fine
needle aspiration biopsy is a reliable first line diagnostic modality
for assessment of these lesions. 76.9% of cases were categorised as
benign by cytology, with a 99.8% negative predictive value. Core
biopsy can then be reserved for the remaining lesions, where it can
be expected to assist in establishing the diagnosis in a further
79.8% of cases, thereby limiting substantially the proportion of
cases requiring diagnostic open biopsy.
These data on the reliability of benign cytology are rendered
even more robust by the fact that long-term follow up through two
independent means has demonstrated no missed cancers among
the lesions recommended for routine re-screening. This additional
follow-up is crucial in bolstering confidence in the results of the
triple assessment process for the discrete rounded lesions detected
during screening mammography.
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